New drug tested for rare kidney diseases shows early safety profile
NCT ID NCT05083364
Summary
This early-phase study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with two rare kidney diseases (C3G and IgA Nephropathy). The main goal was to see how the body processes the drug and to check for side effects before testing it in larger groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Auckland, 1010, New Zealand
-
Research Site 1
Camperdown, New South Wales, 2050, Australia
-
Research Site 1
Gamcheon, Busan, 49267, South Korea
-
Research Site 2
Clayton, Victoria, 3168, Australia
-
Research Site 2
Tbilisi, 0112, Georgia
-
Research Site 2
Cologne, 50937, Germany
-
Research Site 2
Haeundae, Busan, 48108, South Korea
-
Research Site 2
Bangkok, 10400, Thailand
-
Research Site 3
Concord, New South Wales, 2139, Australia
-
Research Site 3
Daegu, Daegu, 42601, South Korea
-
Research Site 3
Chiang Mai, 50200, Thailand
-
Research Site 4
Erlangen, 91054, Germany
-
Research Site 4
Goyang-si, Gyeonggi-do, 10444, South Korea
-
Research Site 4
Oxford, OX3 7LE, United Kingdom
-
Research Site 6
Soeul, 03722, South Korea
-
Research Site 8
Soeul, 05030, South Korea
Conditions
Explore the condition pages connected to this study.